Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Lyell Immunopharma Inc (Lyell) is a clinical-stage cell therapy company. It develops next-generation CAR T-cell therapies for treating hematologic malignancies and solid tumors. The company's activities include the research, development, and manufacturing of cell therapy products. Lyell's pipeline product include LYL314, is a dual-targeting CD19/CD20 CAR T-cell product candidate designed to target both CD19 and CD20, two antigens present on B-cell lymphoma; and solid tumors programs. The company operates across the US. Lyell is headquartered in South San Francisco, California, the US.
Headquarters
United States of America
Address
201 Haskins Way, Suite 301, South San Francisco, California, 94080
Website
lyell.com
Telephone
1 650 6950677
No of Employees
300
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
LYEL (NASD)
Revenue (2024)
$61,000
-53.1%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-46.2%
(2024 vs 2023)
Market Cap*
$327.8M
Net Profit Margin (2024)
XYZ
-211.5%
(2024 vs 2023)
* As of and is in US$
Lyell Immunopharma Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| LYL314: Aggressive Large Cell B-cell lymphoma, Regenerative Medicine Advanced Therapy and Fast Track Designations |
| Solid Tumors Programs |
| XYZ |
| XYZ |
| XYZ |
Competitor Comparison
| Key Parameters | Lyell Immunopharma Inc | Sangamo Therapeutics Inc | Pharmedic Pharmaceutical Medicinal JSC | Allogene Therapeutics Inc | Clondalkin Pharma & Healthcare (Northampton) Ltd. |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | Vietnam | United States of America | United Kingdom |
| City | South San Francisco | Richmond | Ho Chi Minh | San Francisco | Northampton |
| State/Province | California | California | - | California | England |
| No. of Employees | 300 | 183 | 524 | 226 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Rick Klausner, M.D. | Chairman | Executive Board | 2018 | 73 |
| Lynn Seely, M.D. | Chief Executive Officer; Director; President | Executive Board | 2021 | 66 |
| Charles Newton | Chief Financial Officer | Senior Management | 2021 | 54 |
| Stephen Hill | Chief Operating Officer | Senior Management | 2021 | 54 |
| David Shook, M.D. | Chief Medical Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer